BNT162b2 (COMIRNATY)
BLA STN 125742/0

Response to CBER 22 July 2021 Information Request Regarding
Clinical Shell Tables for Study C4591001
Follow-Up #3 (Efficacy 508 Tables)

Response to CBER 03 August 2021 Information Request Regarding
Subject C4591001 1001 10031167 and SAS programs

July 2021
# TABLE OF CONTENTS

1. INTRODUCTION .................................................................................................................3

2. CBER INFORMATION REQUESTS AND SPONSOR RESPONSES .................................3
   2.1. CBER Request 6 from 22 July 2021 Information Request .......................................3
   2.2. CBER Request 1 from 03 August 2021 Information Request ..................................4
   2.3. CBER Request 2 from 03 August 2021 Information Request .................................4
1. INTRODUCTION

Reference is made to BLA STN 125742/0 for COVID-19 mRNA Vaccine (COMIRNATY), for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals ≥16 years of age and to CBER’s 22 July 2022 Information Request received via email from Laura Gottshalk, PhD (CBER) regarding clinical shell tables for Study C4591001.

Further reference is made to the Response to CBER 22 July 2021 Information Request submitted to BLA 125742/0 on 26 July 2021 (Sequence Number 0018), the Response to CBER 22 July 2021 Information Request Follow-up #1 submitted to BLA 125549/0 on 28 July 2021 (Sequence Number 0020) and the Response to CBER 22 July 2021 Information Request Follow-up #2 submitted to BLA 125549/0 on 2 August 2021 (Sequence Number 0028).

Please note the following:

- Responses to CBER 22 July 2021 Information Request Items 3, 4, 5, 7, 8 and 9 were submitted to BLA 125549/0 on 26 July 2021.
- Responses to CBER 22 July 2021 Information Request Items 1 and 2 were submitted to BLA 125549/0 on 28 July 2021.
- Further response to CBER 22 July 2021 Information Request Item 5b was submitted to BLA 125549/0 on 2 August 2021.
- The present response addresses CBER 22 July 2021 Information Request Item 6 in part: The 508 efficacy tables are provided herein, while the safety 508 tables will be provided on 13 August 2021.

Additional reference is made to CBER’s 03 August 2021 Information Request received via email from Michael Smith, PhD (CBER) regarding Subject C4591001 1001 10031167 and SAS programs used to generate efficacy analyses according to CDC definition. Responses to CBER’s 03 August 2021 requests are provided herein as well.

CBER requests are provided below in **bold italics** with Sponsor responses in plain text.

2. CBER INFORMATION REQUESTS AND SPONSOR RESPONSES

2.1. CBER Request 6 from 22 July 2021 Information Request

*Please complete the following tables, based on the Study C4591001 Phase 2/3 populations, limited to participants 16 years of age and older (please exclude participants 12-15 years of age) from the March data cutoff, unless otherwise specified. Please add rows, as needed to list additional items.*
Sponsor Response

The requested efficacy 508 tables are provided in Module 5.3.5.1 C4591001 508 Compliant Efficacy Tables (PDF) and Module 5.3.5.1 C4591001 508 Compliant Efficacy Tables (Word).

The requested safety 508 tables will be provided on 13 August 2021.

2.2. CBER Request 1 from 03 August 2021 Information Request

In your response submitted in STN 125742/0.17 dated July 26, 2021 (to CBER’s comment 4 sent on July 22, 2021), you clarified that Episodes B and C were merged into one single COVID-19 case for Subject C4591001 1001 10031167 because this subject had the severe symptom of hospitalization from 22 November 2020 to 23 December 2020. While hospitalization is a criterion for severe COVID-19 according to the CDC definition, it is not a symptom or criterion defined in the study protocol for COVID-19 case definition. In addition, the first positive PCR result was obtained on 19 December 2020, which was ~1 month after the hospitalization, making it difficult to corroborate that the hospitalization was due to COVID-19. Therefore, we disagree with the mergence of these two episodes based on hospitalization. Please provide updated efficacy analyses accordingly, to exclude this subject, and participants 12 through 15 years of age for the shell tables requested.

Sponsor Response

The efficacy 508 tables for participants ≥16 years of age provided in Module 5.3.5.1 in response to CBER’s 22 July 2021 request (see response in Section 2.1) have been updated accordingly to remove merging of Episodes B and C for Subject C4591001 1001 10031167. As a result, this subject is no longer counted as a COVID-19 case during the blinded placebo-controlled follow-up period in the efficacy tables.

2.3. CBER Request 2 from 03 August 2021 Information Request

Please submit the SAS programs used to generate efficacy analyses according to the CDC-definition, i.e., adc19ef-ve-sev-7pd2-cdc-wo-eval and adc19ef-ve-sev-7pd2-cdc-eval.

Sponsor Response

The requested SAS programs are provided in Module 5.3.5.1.
# Document Approval Record

<table>
<thead>
<tr>
<th>Document Name:</th>
<th>COVID-19 Vaccine - Follow-up 3 (508 Efficacy Tables) for CBER 22 Jul 2021 Request + Response to 03 Aug 2021 Request (Covid Case, SAS Programs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Document Title:</td>
<td>COVID-19 Vaccine - Follow-up 3 (508 Efficacy Tables) for CBER 22 Jul 2021 Request + Response to 03 Aug 2021 Request (Covid Case, SAS Programs)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Signed By:</th>
<th>Date(GMT)</th>
<th>Signing Capacity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perez, John</td>
<td>05-Aug-2021 14:41:31</td>
<td>Final Approval</td>
</tr>
</tbody>
</table>